Accéder au contenu
Merck

C-type natriuretic peptide-modified lipid vesicles: fabrication and use for the treatment of brain glioma.

Oncotarget (2017-04-14)
Jia-Shuan Wu, Li-Min Mu, Ying-Zi Bu, Lei Liu, Yan Yan, Ying-Jie Hu, Jing Bai, Jing-Ying Zhang, Weiyue Lu, Wan-Liang Lu
RÉSUMÉ

Chemotherapy of brain glioma faces a major obstacle owing to the inability of drug transport across the blood-brain barrier (BBB). Besides, neovasculatures in brain glioma site result in a rapid infiltration, making complete surgical removal virtually impossible. Herein, we reported a novel kind of C-type natriuretic peptide (CNP) modified vinorelbine lipid vesicles for transferring drug across the BBB, and for treating brain glioma along with disrupting neovasculatures. The studies were performed on brain glioma U87-MG cells in vitro and on glioma-bearing nude mice in vivo. The results showed that the CNP-modified vinorelbine lipid vesicles could transport vinorelbine across the BBB, kill the brain glioma, and destroy neovasculatures effectively. The above mechanisms could be associated with the following aspects, namely, long circulation in the blood; drug transport across the BBB via natriuretic peptide receptor B (NPRB)-mediated transcytosis; elimination of brain glioma cells and disruption of neovasculatures by targeting uptake and cytotoxic injury. Besides, CNP-modified vinorelbine lipid vesicles could induce apoptosis of the glioma cells. The mechanisms could be related to the activations of caspase 8, caspase 3, p53, and reactive oxygen species (ROS), and inhibition of survivin. Hence, CNP-modified lipid vesicles could be used as a carrier material for treating brain glioma and disabling glioma neovasculatures.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Natriuretic Peptide, C-Type, ≥95% (HPLC)
Sigma-Aldrich
8-(4-Chlorophenylthio)-guanosine 3′,5′-cyclic monophosphorothioate, Rp Isomer triethylammonium salt, ≥98% (HPLC), solid